Our study results indicate that FOXQ1 was upregulated in colon adenocarcinoma, liver hepatocellular carcinoma, pancreatic adenocarcinoma, and ovarian serous cystadenocarcinoma and downregulated in kidney cancer tissue and cell lines, which hints at a major role for FOXQ1 in tumor occurrence and development and its potential as a tumor diagnostic biomarker. This evidence concerns the gene FOXQ1 and colon adenocarcinoma.